Emergent Biosolutions Inc Diversifies Its Revenue

One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1 billion in revenue by 2020.

Metric

Q2 2017

Continue reading


Source: Fool.com